Emerging trends in point-of-care biosensing strategies for molecular architectures and antibodies of SARS-CoV-2

Karuppaiah, Gopi; Vashist, Arti; Nair, M. G.; Veerapandian, Murugan; Manickam, Pandiaraj

doi:10.1016/j.biosx.2023.100324

Cited by 3 publications

(5 citation statements)

References 191 publications

(161 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…94 For patients monitoring the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, identification of possible biomarkers for illness diagnosis is essential. 95 In this direction, Li et al 33 proposed a susceptible quantum sensor for viral RNA detection from patient samples using a diamond NV center. This proposed model can detect as few as a hundred RNA copies of the COVID-19 virus with a false negative rate of less than 1%.…”

Section: Applications Of Quantum Biosensors In Medical Diagnosticsmentioning

confidence: 99%

Review—Quantum Biosensors: Principles and Applications in Medical Diagnostics

Das,

Mazumdar,

Khondakar

et al. 2024

ECS Sens. Plus

View full text Add to dashboard Cite

Originating at the intersection of physics and biosensing, quantum biosensors (QB) are transforming medical diagnostics and personalized medicine by exploiting quantum phenomena to amplify sensitivity, specificity, and detection speed compared to traditional biosensors. Their foundation lies in the fusion of biological entities like DNA, proteins, or enzymes with quantum sensors, which elicits discernible alterations in light emissions when interacting with sample molecules. Their prowess in identifying disease-linked biomarkers presents an avenue for early diagnoses of conditions like Alzheimer's and cancer. Beyond this, they enable real-time monitoring of treatment responses by capturing the dynamism of biomarkers, but QB still face challenges, such as issues of stability, reproducibility, and intricate quantum interactions. Moreover, seamless integration into prevailing diagnostic frameworks necessitates careful consideration. Looking ahead, the evolution of QB navigates uncharted territories. Innovations in fabrication techniques, interdisciplinary collaborations, and standardization protocols emerge as pivotal areas of exploration. This comprehensive discourse encapsulates QB's principles, diverse iterations, and burgeoning medical utilities. It delves into inherent challenges and limitations, shedding light on the potential trajectories of future research. As QB continues to evolve, its potential to redefine medical diagnostics becomes increasingly tangible. The saga of QB resonates with possibilities, poised to reshape the diagnostic landscape profoundly.

show abstract

Section: Applications Of Quantum Biosensors In Medical Diagnosticsmentioning

confidence: 99%

Review—Quantum Biosensors: Principles and Applications in Medical Diagnostics

Das,

Mazumdar,

Khondakar

et al. 2024

ECS Sens. Plus

View full text Add to dashboard Cite

show abstract

“…Pre-concentration of the sample is feasible, but impractical for POC tests. Signal enhancement is a goal that can be pursued through the development of innovative optical reporter systems and the development of new nanotechnology-based approaches [7] , [45] – [47] . As mentioned, in the field of nanoparticles, the first common approach has been to modify the size or structure of commonly used AuNP, which are both critical factors affecting the sensitivity of LFIA [7] .…”

Section: Overview On Serological Detectionmentioning

confidence: 99%

“…Quantum dots are outstanding fluorescent materials with unique optical and electrical properties and many LFIAs have been produced using these labels with enhanced sensitivity [50] , [51] . Other label materials are under evaluation, including latex particles, magnetic nanoparticles and more recently carbon, silica and europium nanoparticles [7] , [47] . In some cases combined label materials have been used to improve sensitivity [52] .…”

Section: Overview On Serological Detectionmentioning

confidence: 99%

“…Although the production on large scale of assays using new technologies is challenging, mainly for the availability of new sophisticated label materials, for many of these results are encouraging, showing a significantly greater performance compared with gold nanoparticle-based commercial kits [47] , [50] , [53] , [54] . Another method to improve sensitivity is the use of an external reader to amplify the signal [20] , [46] .…”

Section: Overview On Serological Detectionmentioning

confidence: 99%

“…Piccoli and coworkers in a landmark study analyzed the specificity and kinetics of neutralizing antibodies elicited by SARS-CoV-2 from a large number of infected subjects and found that the RBD is immunodominant in terms of total antibodies elicited, and is the target of 90% of the neutralizing activity found in the sera/plasma of most individuals evaluated [47] . Several studies now confirm that NAbs against RBD, blocking the interaction with ACE2 receptor, provide the most effective mechanism to neutralize the virus [65] – [67] .…”

Section: Overview On Serological Detectionmentioning

confidence: 99%

See 2 more Smart Citations

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Spicuzza¹,

Campagna²,

Maria³

et al. 2023

AIMSMICRO

View full text Add to dashboard Cite

<abstract> <p>Over the last three years, after the outbreak of the COVID-19 pandemic, an unprecedented number of novel diagnostic tests have been developed. Assays to evaluate the immune response to SARS-CoV-2 have been widely considered as part of the control strategy. The lateral flow immunoassay (LFIA), to detect both IgM and IgG against SARS-CoV-2, has been widely studied as a point-of-care (POC) test. Compared to laboratory tests, LFIAs are faster, cheaper and user-friendly, thus available also in areas with low economic resources. Soon after the onset of the pandemic, numerous kits for rapid antibody detection were put on the market with an emergency use authorization. However, since then, scientists have tried to better define the accuracy of these tests and their usefulness in different contexts. In fact, while during the first phase of the pandemic LFIAs for antibody detection were auxiliary to molecular tests for the diagnosis of COVID-19, successively these tests became a tool of seroprevalence surveillance to address infection control policies. When in 2021 a massive vaccination campaign was implemented worldwide, the interest in LFIA reemerged due to the need to establish the extent and the longevity of immunization in the vaccinated population and to establish priorities to guide health policies in low-income countries with limited access to vaccines. Here, we summarize the accuracy, the advantages and limits of LFIAs as POC tests for antibody detection, highlighting the efforts that have been made to improve this technology over the last few years.</p> </abstract>

show abstract

Hierarchical Nanobiosensors at the End of the SARS-CoV-2 Pandemic

Medrano-Lopez,

Villalpando,

Salazar

et al. 2024

Biosensors

View full text Add to dashboard Cite

Nanostructures have played a key role in the development of different techniques to attack severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some applications include masks, vaccines, and biosensors. The latter are of great interest for detecting diseases since some of their features allowed us to find specific markers in secretion samples such as saliva, blood, and even tears. Herein, we highlight how hierarchical nanoparticles integrated into two or more low-dimensional materials present outstanding advantages that are attractive for photonic biosensing using their nanoscale functions. The potential of nanohybrids with their superlative mechanical characteristics together with their optical and optoelectronic properties is discussed. The progress in the scientific research focused on using nanoparticles for biosensing a variety of viruses has become a medical milestone in recent years, and has laid the groundwork for future disease treatments. This perspective analyzes the crucial information about the use of hierarchical nanostructures in biosensing for the prevention, treatment, and mitigation of SARS-CoV-2 effects.

show abstract

Emerging trends in point-of-care biosensing strategies for molecular architectures and antibodies of SARS-CoV-2

Cited by 3 publications

References 191 publications

Review—Quantum Biosensors: Principles and Applications in Medical Diagnostics

Review—Quantum Biosensors: Principles and Applications in Medical Diagnostics

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies

Hierarchical Nanobiosensors at the End of the SARS-CoV-2 Pandemic

Contact Info

Product

Resources

About